• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Arcutis Biotherapeutics Inc (NQ: ARQT )

    8.310 -0.210 (-2.46%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Arcutis Biotherapeutics Inc

    < Previous 1 2 3 4 5 6 7 Next >
    Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4
    Via Benzinga
    Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Assessing Arcutis Biotherapeutics: Insights From 4 Financial Analysts
    Via Benzinga
    Peeling Back The Layers: Exploring Arcutis Biotherapeutics Through Analyst Insights
    Via Benzinga
    New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Biotherapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
    Via Benzinga
    Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    CAVA Group Posts Strong Q2 Results, Joins Bilibili, Workday And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    Titan Machinery Reports Weak Preliminary Results, Joins Precigen, Gogoro And Other Big Stocks Moving Lower In Thursday Pre-Market Session
    Via Benzinga
    CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    ARQT Stock Earnings: Arcutis Biotherapeutics Beats EPS, Beats Revenue for Q2 2024
    ARQT stock results show that Arcutis Biotherapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    7 Biotech Stocks to Keep on Your Clinical Radar
    Biotech stocks have always been relevant. However, with the latest shift in the political race, this sector is bound to grab more eyeballs. 
    Via InvestorPlace
    Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    FDA Approves Expanded Use Of Arcutis Biotherapeutics' Eczema Drug For Patients As Young As 6 Years
    FDA approved Arcutis Biotherapeutics' sNDA for Zoryve cream 0.15% for mild to moderate atopic dermatitis in patients aged six and older. Zoryve provides a steroid-free treatment option. Significant... 
    Via Benzinga
    Exposures Product Safety
    FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Intapp, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session
    Via Benzinga
    The 7 Best Under $10 Stocks to Buy in July 2024
    We’re finding big opportunities in some of the best stocks under $10 a share. In fact, here are seven you may want to jump into now. 
    Via InvestorPlace
    Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
    Via Benzinga
    Have $5-10? 7 Affordable Stocks That Are About to Breakout.
    These stocks are already showing gains this year, but they are all still affordable stocks ready to breakout. 
    Via InvestorPlace
    Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.